Physician profile
Celina Accetta
NPI 1376438598
$2,335.35
in general payments reported to CMS, 2019-2025
26 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $295.84 | 2025 | |
| Ucb, INC. | $290.62 | 2025 | Fintepla, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $219.74 | 2025 | Uzedy, Austedo Xr, Ajovy |
| Abbvie INC. | $219.39 | 2025 | |
| Lundbeck LLC | $195.65 | 2025 | Vyepti, Rexulti |
| Vanda Pharmaceuticals INC. | $147.84 | 2025 | Ponvory |
| Lilly USA, LLC | $119.28 | 2025 | Kisunla |
| Neurelis, INC. | $112.71 | 2025 | Valtoco |
| Tanabe Pharma America, INC. | $89.24 | 2025 | Radicava |
| Amneal Pharmaceuticals LLC | $74.02 | 2025 | Crexont |
| Celgene Corporation | $71.38 | 2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $70.47 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $57.32 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $48.02 | 2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $42.58 | 2025 | Wainua |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.84 | 2025 | |
| Aucta Pharmaceuticals, INC. | $36.17 | 2025 | Motpoly Xr |
| Pfizer INC. | $29.35 | 2025 | |
| Otter Pharmaceuticals, LLC | $27.41 | 2025 | Sympazan |
| Genentech USA, INC. | $24.47 | 2025 | Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $24.02 | 2025 | |
| Genzyme Corporation | $23.40 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $21.67 | 2025 | |
| Jazz Pharmaceuticals INC. | $21.48 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $18.15 | 2025 | Lumryz |
| Biogen, INC. | $16.29 | 2025 | Tysabri, Vumerity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celina Accetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.